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1416Objective: Both retrograde femoral and subclavian artery catheterization techniques have been described as the
most common methods for the implantation of the Medtronic CoreValve percutaneous aortic valve (Medtronic
Inc, Minneapolis, Minn). The subclavian artery has been shown to be a safe and effective alternative access route
in patients with unfavorable femoral access. Of the patients who are identified as candidates for subclavian artery
access, a subset possess a patent left internal thoracic artery to left anterior descending artery. This patent left
internal thoracic artery presents an additional anatomic and clinical variable that must be taken into consider-
ation to ensure procedural safety and efficacy. We describe the Medtronic CoreValve percutaneous aortic valve
implantation using the subclavian arterial approach in patients with a patent left internal thoracic artery and
report our study’s findings.
Methods: The CoreValve percutaneous aortic valve is a self-expandable nitinol-based frame with a porcine
pericardial valve. The subclavian access was created by a small infraclavicular surgical incision to expose the ar-
tery. Rapid ventricular pacing was used to reduce cardiac output to perform the balloon aortic valvuloplasty via
a 12F sheath inserted into the subclavian artery. An 18F sheath was then inserted into the artery down into the as-
cending aorta and used for introduction of the delivery catheter and implantation of the percutaneous aortic valve.
Results: With the use of this method, 19 patients (76  13 years) whose surgical risk was deemed excessive
because of severe comorbidity and in whom transfemoral catheterization was considered unfeasible or at risk
of severe complications have received implants. Subclavian artery or left internal thoracic artery injury did
not occur in any patient. Two deaths occurred. One patient died of right coronary artery occlusion during the
procedure, and one patient died 48 hours after the procedure as the result of a tamponade after the temporary
pacemaker wire ablation.
Conclusions: This initial experience suggests that subclavian transarterial aortic valve implantation in patients
with a patent left internal thoracic artery to left anterior descending artery is feasible and safe with satisfactory
short-term outcomes. (J Thorac Cardiovasc Surg 2012;144:1416-20)Many patients with severe aortic valve stenosis cannot un-
dergo open surgery using cardiopulmonary bypass because
of excessive surgical risk and advanced age. Prognosis with
optimal medical management is poor.1,2
Transcatheter aortic valve implantation (TAVI) is a thera-
peutic option for high-risk patients with aortic stenosis. Tech-
nical challenges and associated risks of TAVI are still a limit
to the development of this technology and remain under
active investigation in many medical centers.3-5 An ever-
growing series of reports reflect the encouraginge CHRU de Lillea and Clinque Clairval,b Marseille, France.
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The Journal of Thoracic and Cardiovascular Surdevelopments in the field, and a large number of remaining
issues, mainly clinical, seem increasingly likely to be solved.
Patient selection requires a complete study of different
arterial access points, such as the aorta, aortoiliac, and
femoral arteries. However, in some patients, peripheral
artery disease may render iliofemoral access difficult or
even impossible. Retrograde femoral access may be chal-
lenging because of heavily diseased, tortuous, or calcified
femoral and iliac arteries. These obstacles increase the
risk of procedural failure or vascular injury with potentially
lethal complications. The existence of this population
with high vascular risk has led to the development of trans-
apical, transaortic, or subclavian access techniques largely
described in the medical literature.6-8 All these techniques
offer the advantage of avoiding access site problems and
facilitating valve delivery. However, the transapical
approach (requiring thoracotomy) and the transaortic
approach (requiring partial sternotomy or thoracotomy)
are intricately more invasive, and therefore high-riskgery c December 2012
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
LAD ¼ left anterior descending
LITA ¼ left internal thoracic artery
TAVI ¼ transcatheter aortic valve implantation
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respiratory dysfunction or a calcified ascending aorta.
Moreover, a number of complications have been reported
after the introduction of a percutaneous valve holder
through the apex of the left ventricle.9,10 In addition,
although feasible, redo sternotomy in patients with patent
grafts remains a risky procedure.
In centers where the heart team approach of TAVI is
effective, using the axillary or subclavian artery, because
of its safety, effectiveness, and less-invasive nature, became
obvious as a second option after the femoral artery for
introducing the device.11,12 However, patients undergoing
coronary artery bypass grafting (CABG) remained
challenging and potentially at higher risk of theoretic
myocardial hypoperfusion. In this prospective study, we
aimed to describe the implantation technique, procedural
tips and tricks, and clinical outcome assessed up to 30
days after TAVI using axillary artery access in patients
who have a patent left internal thoracic artery (LITA) to
left anterior descending (LAD) artery. This prospective
study, performed between January 2010 and June 2011,
was performed on 19 consecutive patients recruited for
this study.
MATERIALS AND METHODS
Patients
A prospective, single-arm study was performed. Patients with severe
symptomatic aortic stenosis were referred for a percutaneous procedure
because of multiple comorbidities and excessive surgical risk. All patients
had a surgical history of CABG with a documented patent LITA to LAD.
Our objective was to evaluate the feasibility, safety, and clinical outcomes
of TAVI via subclavian or axillary artery access of the 18F Medtronic
CoreValve System (Medtronic Inc, Minneapolis, Minn) in this category
of patients. The cases were selected following the guidelines of the Euro-
pean Society of Cardiology. A heart team of senior interventional cardiol-
ogists, cardiac surgeons, and anesthetists formally reviewed patients with
a consensus that patients did not have a reasonable surgical option. Patient
preference alone for TAVI was not an acceptable reason for inclusion.
Informed consent was obtained. All patients underwent transthoracic
echocardiography, iliofemoral, and coronary angiography. Whole-body
computed tomography angiography and Doppler echocardiography were
used to assess left subclavian, axillary, and LITA diameters and patency.
Short segments of calcified or focal stenosis of subclavian or axillary
arteries were not considered an exclusion criterion.
Prosthetic Valve System
The Medtronic CoreValve System consists of porcine pericardium cut
into a trileaflet pattern mounted within a nitinol frame. The diameter ofThe Journal of Thoracic and Carthe aortic annulus was measured using the transthoracic echocardiography
parasternal long-axis view immediately below the insertion point of the
valve leaflets. Because the aortic annulus is not circular, a computed
tomography scan was also used to measure the minimum and maximum
diameter. An annulus diameter of 20 to 23 mm was considered appropriate
for a 26-mm diameter prosthesis and 23 to 27 mm for a 29-mm prosthesis.
Both prostheses require an 18F introducer sheath. An axillary arterial diam-
eter of 7 mm or greater was considered adequate for implantation.
Patients were premedicated with a loading dose of clopidogrel and
aspirin and received an intravenous injection of 1 g cefazolin immediately
before the procedure. The latter was performed in a catheterization labora-
tory with operating room sterility precautions. A femoral access was used,
and a 6F pigtail catheter was inserted for control angiograms during valve
implantation, as well as a vein access for the temporary pacemaker lead
used for rapid pacing during valvuloplasty. Heparin 50 U/kg was adminis-
tered intravenously on completion of vascular access.
The proximal subclavian artery (segment 2) was exposed through
a small infraclavicular incision. In those patients, unlike in routine subcla-
vian prosthesis implantations, we did not use 5-0 Prolene continuous purse-
string sutures to achieve controlled and careful closure of the artery at the
end of the procedure. A 6F sheath was inserted, through a 1-cm contra-
incision made 2 cm outside of the main incision, in the middle of the
exposed segment of the artery, using a percutaneous technique. The
contra-incision allows for an excellent stabilization of the 18F sheath and
the valve catheter throughout the procedure without achieving a purse-
string suture. The native valve was crossed using a conventional technique
that includes use of a straight wire. After hemodynamic transvalvular
gradient and end-diastolic ventricular pressure measurement, a manually
preshaped stiff wire was placed into the ventricular cavity. A 12F sheath
was then inserted into the subclavian access under fluoroscopy. Balloon
valvuloplasty was inserted, and valvuloplasty was performed using
a 22-mm balloon (Nucleus; NuMED Inc, Hopkinton, NY) for the 26-mm
Medtronic CoreValve prosthesis or 25-mm balloon for the 29-mm prosthe-
sis. After balloon deflation, the rapid pacing was stopped and the balloon
catheter was withdrawn. We then achieved progressive artery dilatation
using increased dilatator diameters (14F, 16F, and 18F). This step allowed
assessing any myocardial perfusion impairment potentially reflected by
electrocardiogram monitoring. The 18F sheath was then carefully inserted,
and its progression was followed using fluoroscopic guidance. An aortic
angiography was performed and displayed during the procedure to facili-
tate subsequent positioning of the sheath and prosthesis. The tip of the
sheath was positioned in the upper part of the ascending aorta. The valve
was then advanced and deployed using repeated fluoroscopic controls.
The prosthesis was positioned so that it protruded less than 80 mm out of
the calcified native valve leaflets into the left ventricular cavity. During
prosthesis implantation, no rapid pacing was used and effort was made
to maintain blood pressure above 100 mm Hg throughout the procedure,
except during valvuloplasty and a short period of time during valve deploy-
ment. A coordinated approach was used wherein 1 operator maintained
ideal valve positioning by pulling slowly on the catheter during valve
release, while the second operator turned the release knob to deliver the
valve. Aortic root angiographies were performed to assess valve position
during implantation. After full release of the valve, the stiff wire position
was maintained into the left ventricular cavity and a pigtail was advanced
to measure the transvalvular gradient and then removed carefully. Aortic
root angiography and echocardiography were performed to reassess valve
competency, using standard criteria, and to evaluate the aortic regurgitation
severity. After procedure completion, the subclavian arterial access sitewas
surgically repaired. To achieve optimal artery repair, no purse string was
used (Figure 1). Indeed, we preferred direct reparation at the end of the
procedure. Two clamps were placed above and below the site of arterial
puncture. This will temporarily interrupt the blood flow, but not at the level
of the LITA. We preferred to repair the artery using interrupted 5-0 Prolene
sutures to prevent vascular constriction and artery thrombosis. The clampsdiovascular Surgery c Volume 144, Number 6 1417
FIGURE 1. Angiographic control showing flow persistence in the
subclavian and internal thoracic artery (continuous blue arrow) despite
the presence of the 18F sheath in the subclavian artery (discontinued
blue arrow).
TABLE 1. Baseline characteristics
Age, y, mean  SD 76  13 y
Angina, n (%) 0%
Heart failure, n (%) 26%
NYHA III–IV failure class 40%
Syncope, n (%) 13.3%
Male gender, n (%) 46.2%
Diabetes mellitus, n (%) 20%
Coronary heart disease, n (%) 53.3%
Prior angioplasty, n (%) 20%
Renal dysfunction,* n (%) 6.6%
Logistic euroSCORE predicted mortality, mean  SD,% 25  13
Left ventricle ejection fraction% mean 49  10
euroSCORE, European System for Cardiac Operative Risk Evaluation; NYHA, New
York Heart Association; SD, standard deviation. *Estimated glomerular filtration
rate>60 mL/min.
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achieving direct angiographic control of the subclavian artery. Papaverine
could have been used in case of vascular spasm. No patch reparation was
required in our patients.
Patients were then transferred to the intensive care unit for 24 to 48
hours of observation. They continued taking aspirin indefinitely and clopi-
dogrel for 6 months. Clinical follow-up and transthoracic echocardiograms
were performed within 24 hours of the procedure and at 1 and 4 weeks after
the device implantation.TABLE 2. Procedural outcome
Successful valvuloplasty 100%
Successful prosthesis implantation 100%
Death, intraprocedure 1
Stroke, minor 0
Cardiac perforation 1
Ventricular fibrillation 0
Emergent cardiac surgery 0
Transfusion rate  2 units 41%
Hospital stay (d) 9.4
Myocardial infarction 0%RESULTS
Patient Outcome
Valve implantation was attempted in 19 consecutive
patients between January 2010 and June 2011. Complete
follow-up was performed in all patients. Preoperative char-
acteristics are shown in Table 1. All enrolled patients had
severe symptomatic aortic stenosis with a mean transvalvu-
lar gradient of 42  15 mm Hg. The pre-procedural mean
aortic valve area was 0.55  0.35 cm2. The procedure
was performed under general anesthesia. The use of trans-
esophageal echocardiographic guidance was not systematic
and left to the discretion of the operators. Percutaneous
placement of the 18F sheath was successful in all cases.
No vascular complication requiring surgical repair was
observed. In 1 patient, the repositioning attempt resulted
in a valve position that was too high because of initially
low valve implantation. The valve was partially pulled out
from the aortic root and positioned in the upper part of
the ascending aorta; a second valve was successfully
implanted using the same arterial access.1418 The Journal of Thoracic and Cardiovascular SurProsthesis implantations were uneventful in this series.
There was 1 intraprocedural death due to right coronary
artery occlusion documented by angiography during the
procedure. Despite previous CABG surgery, the patient
had severe symptomatic coronary artery disease that has
required a recent angioplasty on the right coronary artery
2 months before the TAVI. A severe intra-stent restenosis
occurred, causing an acute myocardial hypoperfusion.
Two days after the procedure, another patient died of
a tamponade that occurred on temporary pacemaker wire
ablation. Intraoperative and postoperative details are shown
in Tables 2 and 3.
Valve Function
Paravalvular leak, as assessed immediately after the
procedure by angiography and echocardiography controls,
was trivial (grade 0–1) in most of the cases (n ¼ 15). There
was no severe postprocedural aortic regurgitation (grade3).
Valve function as assessed by echocardiography within
24 hours after implantation, before discharge, and at 1
month remained essentially unchanged (Table 4). In 3
patients, moderate paravalvular leak occurred immediately
after valve implantation and appeared to be caused by an
insufficiently expanded frame. Additional valvuloplasty,
during the same procedure, using the same diameter
balloon, under rapid pacing, reduced severe paravalvulargery c December 2012
TABLE 3. Postprocedural outcome (follow-up of 30 days)
Death 1 patient
Thromboembolism 0%
Transient ischemic attack 0%
Myocardial infarction 1 patient
Aortic dissection 0%
Tamponade 1 patient
Conversion to surgery 0%
NYHA class I–II 100%
endocarditis 0%
NYHA, New York Heart Association. Values are n (%) unless otherwise stated.
Modine et al Acquired Cardiovascular Diseaseinsufficiency to trivial in these 3 patients without apparent
damage to the valve leaflets, as assessed by the absence of
a central leak during the echocardiographic control. At 30
days and on the last day of follow-up, the mean paravalvular
leak remained unchanged.A
C
DDISCUSSION
The scope of heart valve disease that might benefit from
percutaneous valve therapy is in motion. TAVI represents
a less-invasive alternative heart surgery for treatment of
severe aortic stenosis in elderly and high-risk patients.13
However, major concerns remain mainly related to the
access route and to the betterment of prosthesis implanta-
tion. In patients with iliofemoral arteriopathy, transfemoral
access may turn out to be an unfeasible or too high-risk
procedure. When a transarterial route is not accessible,
transapical or transaortic approaches may be interesting
alternatives in some patients.14 However, those alternatives
are intricately more invasive because they require a thora-
cotomy with left ventricular puncture or partial sternotomy,
and therefore may not be suitable in fragile patients,
especially in those with severe respiratory or ventricular
dysfunction or a calcified ascending aorta. In addition,
although feasible, these alternatives are also risky in case
of previous cardiac surgery. It has been shown that TAVI us-
ing the subclavian or axillary approach is feasible and safe,
as well as familiar to some cardiovascular surgeons.11,12 In
comparison with the transfemoral approach, positioning the
valve and controlling its release proved to be considerably
easier and offered greater movement precision. The short
distance between the subclavian artery and the aortic
annulus might explain the increased control of the 18F
sheath and delivery catheter. The subclavian and proximalTABLE 4. Echocardiographic characteristics
Baseline Postprocedure 1 mo
Gradient mm Hg, mean 42  15 8  4 7.8  3.9
Valve area,* cm2, mean  SD 0.55  0.35 1.48  0.35 1.52  0.38
Aortic paravalvular
insufficiency, grade  2
NA 20% 5%
N/A, Not applicable; SD, standard deviation. *Derived from continuity equation.
The Journal of Thoracic and Caraxillary arteries are usually of good size and only
moderately diseased even in the most elderly population
groups. The vessels can be approached through an infra-
or a supraclavicular incision. The supraclavicular incision
may be preferred especially in patients with pacemakers
implanted in the infraclavicular area to avoid risk of
infective endocarditis.12
However, in patients with a medical history of CABG
with a patent LITA, this route could be challenging.15
Thus, only experienced teams should consider this access
route. Indeed, some technical conditions associated with
this procedure, described above, should be respected (eg,
progressive artery predilation, maintaining high blood
pressure, interrupted sutures). Indeed, a risk of LITA dam-
age during the procedure and a theoretic impairment of
myocardial perfusion through the LAD should be kept in
mind. Of note, in this series, the right subclavian artery
was not used. Currently, in our centers we perform percuta-
neous femoral, direct aortic, carotid, subclavian, and trans-
apical approaches to achieve valve implantations. On the
basis of screening results, we always prefer the less-
invasive approach in patients. Although the direct aortic ap-
proach is feasible in this subset of patients with previous
CABG surgery and patent arterial and venous grafts, there
is a risk of graft lesion and the subclavian, less-invasive
approach may be effective and thus should be considered
for implantation.
This prospective study reports a real-life experience of
selected high-risk patients with degenerative aortic valve
stenosis who were treated with TAVI by the same surgeon
(TM) using left subclavian access. The results of this series
of 19 patients, in accordancewith similar recently published
articles, confirm the feasibility of the procedure.11,12,16,17
Optimal positioning of the prosthetic valve is mandatory
to reduce risk of embolization, paravalvular insufficiency,
and coronary obstruction. Because of the shorter distance
between the arterial entry point and the implantation site,
when compared with the femoral access, axillary or
subclavian access provides better sheath and delivery
catheter stability, increasing the accuracy of valve
positioning and reducing procedure time. From an
anesthetic point of view, maintaining blood pressure
greater than 100 mm Hg is recommended throughout the
procedure. This could have been observed in our patients
except during valvuloplasty and a short period of time
during valve deployment. Electrocardiogram monitoring
confirmed the good myocardial tolerance throughout the
procedure. In addition, angiographic controls showed no
impairment of LITA flow despite the 18F sheath in the
subclavian artery (Figure 1). Moreover, direct subclavian
vascular repair was easily performed and surgical control
of the access point allowed (Figure 2) for limited risk of
immediate or delayed vascular complications as observed
with the percutaneous transfemoral access.diovascular Surgery c Volume 144, Number 6 1419
FIGURE 2. Subclavian artery aspect before surgical closure after TAVI.
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and patent LITAs are eligible for the subclavian approach.
Nevertheless, this access route should be considered
carefully because of the potential risk of subclavian dissec-
tion, which may compromise graft patency. We recommend
a minimum 7.5-mm artery diameter to ensure a safe ap-
proach as demonstrated by our findings.
We preferred to calculate the transfusion rate to provide
a reliable indication of major bleeding consequences on
patients. In our series, transfusion rate was acceptable in
a population exposed to preoperative anemia (41% of
patients,  2 units), although no bleeding complications
occurred throughout the study. Although stroke is a known
risk of routine balloon valvuloplasty,18 none of our patients
experienced an ischemic cerebrovascular event. Severe
(grade>2) paravalvular leak was not observed in our series.
Paravalvular leaks altogether were uncommon and seemed
to result from large calcifications positioned between the
prosthesis and the annulus causing incomplete sealing.
Three patients required iterative balloon valvuloplasty
inside the prosthesis, each during the same procedure and
using the same valvuloplasty balloon diameter, to reduce
paravalvular leaks responsible for aortic regurgitation
greater than grade 2. In this study, hospital stay duration
was acceptable and comparable to previous reported expe-
rience.11 Confirmation of the efficacy and safety of this
technique will require a larger population. This report
shows that the outcome of TAVI using the subclavian route
in patients with a patent LITA compares favorably with our
experience of transfemoral and transaxillary (without a pat-
ent LITA) implantations and provides improved valve
implantation accuracy that results in lower average grades
of paravalvular leakage and complications.
CONCLUSIONS
The current application of TAVI is limited to patients who
are high-risk candidates for surgical valve replacement.
Among this population, a number of patients do not meet1420 The Journal of Thoracic and Cardiovascular Surthe criteria for transfemoral implantation because of the
lack of suitable arterial access. The transaxillary or subcla-
vian approach in these patients represents a feasible, safe,
and technically interesting alternative, even in patients
with a patent LITA to LAD.
The authors thank Dr Christopher Hurt for help in editing this
article.
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